




# PHARMACEUTICAL 2017

Larimar Therapeutics Inc.  
Rank 138 of 313





## PHARMACEUTICAL 2017

Larimar Therapeutics Inc.  
Rank 138 of 313

The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 403% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is -142%, being 274% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	130,899
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,894
Liabilities, Non-Current	0
Other Assets	61
Other Compr. Net Income	127
Other Expenses	0
Other Liabilities	0
Other Net Income	347
Property and Equipment	661
Research and Development	39,936
Revenues	0
Selling, General and Administrative Expense	18,289

Output Variable	Value in 1000 USD
Assets	131,621
Liabilities	9,894
Expenses	58,225
Stockholders Equity	121,727
Net Income	-57,878
Comprehensive Net Income	-57,814
Economic Capital Ratio	-142%

